LCP-AtorFen
- Generic Name
- LCP-AtorFen
- Drug Type
- Small Molecule
- Background
LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG).
- Indication
Investigated for use/treatment in hyperlipidemia.
12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Veloxis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT00664859
- Locations
- 🇺🇸
Radiant Research, 515 N State St, Suite 2700, Chicago, Illinois, United States
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
- Conditions
- Dyslipidemia
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Veloxis Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT00504829
- Locations
- 🇺🇸
Radiant Research, 515 N State Street, Suite 2700, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.